XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Note 7 - Stock-based Compensation and Equity Transactions
3 Months Ended
Jan. 31, 2025
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

Note 7 Stock-based compensation and equity transactions

 

On December 2, 2024, we granted 47,500 incentive stock options to seven managers. The shares of incentive stock options vest equally over four years as follows: (i) one-quarter of the options shall vest on December 2, 2025 and (ii) the remaining options shall vest in three equal annual installments over the next three years.

 

On January 13, 2025, we granted a total of 82,500 shares of restricted stock and 165,000 incentive stock options to two managers and three officers. The shares of restricted stock and incentive stock options vest over four years as follows: (i) one-quarter of the restricted shares and options shall vest on January 13, 2026 and (ii) the remaining restricted shares and options shall vest in 12 equal quarterly installments over the next three years.

 

No other shares or options were granted to Company employees during the three months ended January 31, 2025 and 2024.

 

The fair value of each option granted during the three months ended January 31, 2025 and 2024 was estimated on the grant date using the Black-Scholes option pricing model with the following assumptions: 

 

   

Three Months Ended January 31,

 
   

2025

   

2024

 

Weighted average volatility

    44.37 %     53.32 %

Expected dividends

    0.00 %     0.00 %

Expected term (in years)

    6.14       7.01  

Risk-free interest rate

    4.54 %     4.00 %

Weighted average fair value of options granted during the year

  $ 1.85     $ 1.76  

Weighted average fair value of options vested during the year

  $ 2.20     $ 2.94  

 

Expected volatilities are based on historical volatility of our stock price and other factors. We used the historical method to calculate the expected life of the 2025 and 2024 options granted. The expected life represents the period of time that options granted are expected to be outstanding. The risk-free rate is based on the U.S. Treasury rate with a maturity date corresponding to the options’ expected life. The dividend yield is based upon the historical dividend yield.

 

Company stock option plans

 

Descriptions of our stock option plans are included in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the year ended October 31, 2024. A summary of the status of the options granted under our stock option plans as of January 31, 2025 and the changes in options outstanding during the three months then ended is presented in the table that follows:

 

   

2025

 
   

Shares or

   

Weighted

 
   

Price Per

   

Average

 
   

Share

   

Exercise Price

 

Outstanding at beginning of November 1, 2024

    874,816     $ 5.10  

Options granted

    212,500     $ 3.97  

Options exercised

    (50,623 )   $ 4.07  

Options canceled or expired

    (25,000 )   $ 8.69  

Options outstanding at January 31, 2025

    1,011,693     $ 4.82  
                 

Options exercisable at January 31, 2025

    525,057     $ 5.67  
                 

Options vested and expected to vest at January 31, 2025

    1,011,693     $ 4.82  
                 

Option price range at January 31, 2025

 

$1.90

- $8.69          
                 

Aggregate intrinsic value of options exercised during year

  $ 43,756          

 

 

Weighted average remaining contractual life of options outstanding as of January 31, 2025: 7.41 years

 

Weighted average remaining contractual life of options exercisable as of January 31, 2025: 5.98 years

 

Weighted average remaining contractual life of options vested and expected to vest as of January 31, 2025: 7.41 years

 

Aggregate intrinsic value of options outstanding at January 31, 2025: $1,037,000

 

Aggregate intrinsic value of options exercisable at January 31, 2025: $330,000

 

Aggregate intrinsic value of options vested and expected to vest at January 31, 2025: $1,037,000

 

As of January 31, 2025, $994,000 and $888,000 of expenses with respect to nonvested stock options and restricted shares, respectively, has yet to be recognized but is expected to be recognized over a weighted average period of 1.8 and 1.5 years, respectively.

 

Stock option expense

 

During the three months ended January 31, 2025 and 2024, stock-based compensation expense totaled $195,000 and $255,000, respectively, and was classified in selling and general expense.